ArticleUpdates in surgery2026
Multimodal AI approach combining deep learning imaging and clinical machine learning for pancreatic cancer detection.
Article in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular Imaging in Pancreatic Cancer: Current Applications and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) has poor prognosis due to late diagnosis, limitations of computed tomography (CT) imaging, and low accuracy of clinical biomarkers. This study aimed to develop and validate a multimodal artificial intelligence (AI) approach integrating imaging-based deep learning (DL) and clinical data-driven machine learning (ML) to improve PDAC diagnosis. A retrospective cohort of 158 patients (123 PDAC, 35 benign) undergoing pancreatic surgery was analyzed. A YOLOv8-based DL model was trained on contrast-enhanced CT scans to detect pancreatic lesions, while clinical data (age, sex, serum CA19-9) were analyzed with a Random Forest ML classifier. Predictions from both models were combined into a multimodal fusion model, optimized to maximize diagnostic accuracy. Performance metrics included precision, recall, accuracy, F1-score, and ROC-AUC. The imaging-based DL model achieved strong tumor detection performance (mAP: 87.0%, precision: 86.5%, recall: 81.2%). The clinical ML model showed excellent specificity (precision: 100%, ROC-AUC: 0.931) but limited sensitivity (60%). The multimodal AI fusion model outperformed both individual models, significantly improving sensitivity, specificity, and overall diagnostic accuracy. A multimodal AI strategy integrating DL imaging analysis with ML-based clinical predictions markedly enhances diagnostic performance in pancreatic cancer. This approach offers potential as an effective decision-support tool, facilitating earlier diagnosis and optimized clinical decision-making.
Indexed as
Identifiers
42053950What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.